Future therapy in systematic lupus erythematosus
DOI:
https://doi.org/10.31053/1853.0605.v68.n2.21537Keywords:
systematic lupus erythematosusAbstract
Systemic Lupus erythematosus (SLE) is the model of systemic autoimmune disease characterized by multiple organ involvement and fluctuating disease activity. The prognosis of SLE improved significantly in the last decades and not only the possibility of greater therapeutic options but other factors such as the development of strategies related to the prevention and treatment of cardiovascular risk factors, infection control and immunization contributed to this advance.
Downloads
References
Wallace D. Management of Lupus Evrythematosus recent insights. Curr. Opin. Reumatol. 2002; 14 :212-219
Urowitz, MB and GladmanD.D How to improve morbidity and mortality in Lupus. Rheumatology 2000.39; 238-244
Wallace DJ. What’s new in the management of lupus since 2000?. J Clin Rheumatol 2006;12: 307-13
Mount GR, Gilliand WR. Emerging biological therapies in systemic lupus erythematosus. Clinical Pharmacology & Therapeutics 2008;83: 167-171
Schneider, M. Exploring new territory: considering the future. Lupus 2007;16: 221-226
Looney. RJ, Anolik J, Sanz I. New Therapies for SLE: celular targets. Rheum. Dis Clin North Am 2006;32: 201-215
Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimec mouse human monoclonal antibody to CD20. Blood 1994;83: 435-45
Alas A, Ng CP, Bonavida B. Rituximab modifies the cisplatinmitochondrial signalling pathway, resulting in apoptosis in cisplatin non-Hodgkins lymphoma. Clin Cancer Res 2002; 8:836-48
Anolik JH, Campbell D, Felgar RE ET AL. The relationship of fcgrllla genotype to degree of B cell deplotion by rituximab in the treatment for systemic lupus erythematosus. Arthritis Rheum 2003; 48:455-59
Anolik JH, Barnard J, Cappione A et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthitis Rheum 2004; 50:3580-3590
Maloney DG, Smith B, Rose A. Rituximab mechanism of action and resistance. Semin. Oncol 2002; 29:2-9
Leandro MJ, Edwards JC, Cambridge G et al. An open study of B lymphocyte depletion in systemic lupus eryhematosus. Arthitis Rheum 2002; 46:2673-77.
Leandro MJ, Edwards JC, Cambridge G et al. B-cell depletion in the treatment of the patients whit systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology 2005; 44:1542-45
NG KP, Leandro MJ, Edwards JC, et al. Repeated B cell Depletion in treatment of refratory systemis lupus erythematosus. Ann rheum Dis 2006; 65:942-45
NG KP, Cambridge G, Leonardo MJ et al. B cell depletion therapy in systemic lupus erythematosus: long – term follow up and predictors of respone. Ann Rheum Dis 2007; 66:1259-62
Looney RJ, Anolik H, Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I-II dose escalation trial of rituximab. Arthitis Rheum 2004; 50:2580-62
Sfikakis PP, Boletis JN, Lionaki S, ET AL. Remision of proliferative lupus nephritis following B cell depletion therapy is preceded by dwon-regulation of the T cell costimulatory molecule CD40 ligan: an open label trial. Arthritis Rheum 2005; 52:501-13
Gunnarsson I, Sundelin B, Jonsdottir T et al. Histopathologic and clinic outcome of rituximab treatment un patients with cyclophosphamide – resistant proliferative lupus nephritis. Arthtitis Rheum 2007; 56:1263-72
Vigna-Perez M, Hernandez-Castro B, Paredes-Sharopulos O et al. Clinic and immunological effects of rituximab in patientss with lupus nephritis refractory to conventional therapy. Arthitis Res Ther 2006; 8:R83
Catapano F, Jones R, Chaudhry A et al. Remission, relapse and re-treatment of 26 SLE patients with rituximab. Lupus 2008; 17:015
Bhat P, Radhakrishnan J. B lymphocytes and lupus nephritis: New insigths in to pathogenesis and targeted therapies. Kidney International 2008; 73:261-268.
Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized , double.blind, phase II/III systemic lupus erythematosis evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222-33.
n BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis : the lupus nephritis assessment with rituximab (LUNAR) study. Arthritis Rheum 2009,69: 429.
Ramos Casals M, Soto MJ, Cuadrado MJ, Khamashta MA.Rituximab in Systemic Lupus Erythematosus : A systematic review of off label use in 188 cases. Lupus 2009;18:767-76.
Catuogno M et al. FERUM sickness associated with rituximab in a patient with hepatitis C virus related mixed cryoglobulinaemia. Rheumatology (Oxford)2005,44:406.
Calabrese LH, Molloy ES, Hauang D et al. Progressive multifocal leukoencephalopathy in rheumatic disease. Arthritis Rheum 2007; 56:2116-2128
Beger JR, Koralnik IJ. Progressive multifocal leukoencephalopaty and natalizumab-unforeseen consequences. N Engl J Med 2005; 353:414-16
Tedder TF, Tuscano J, Sato S et al. CD22, a B lymphocty-specific adhesión molecule that regulates antigen receptor signalling. Annu Rev Immunol 1997; 15:481-504
Dorner T, Kaufmann J, Wegener WA et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus eryhtematosus. Arthritis Res Ther 2006; 8:R74.
Isenberg DA. Treating patients with B-cell depletion. Lupus 2008; 17:400-404
Thompson JS, Bixler SA, Qian F et al. BAAF-R, a novel TNF receptor that specifically interacts with BAAF. Science 2001; 293:2108-11
Moore PA, Belvedere O, Orr A et al. BLyS: Member of the tumor necrosis factor family and B lymphocyte simulator. Science 1999; 285:260-63
Roschke V, Sosnovtseva S, Ward CD et al. BLyS and APRIL from biologiclly active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J immunol 2002; 169:4314-4321
Stohl W, Metyas S, Tan SM et al. C Lymphocyte stimulator over-expression in patients with systemic lupus erythematosus: longitunidal observations. Arthritis Rheum 2003; 48:3475-3486
Furie R, Sthol W, Ginzler E, et al. Safety pharmacokinetic and pharmacodynamic results of a phase I single and doublé dose escalation study of lymphostat-B (human monoclonal anti-body to BLyS) in SLE patients. Arthritis Rheum 2003; 48:S377
Petri M, Furie R, Ginzler EM, et al. Belimumab (fully human monoclonal antibody to BLyS) improved or stabilized Systemic Lupus erythematosus (SLE) disease a activity over 2.5 years of therapy. Lupus 2008; 17:016
Ginzler EM, Chatham W, Stohl W et al. Correlation of biomarker changes with clinical improvement over 2.5 years of Belimumab (fully human monoclonal antibody to BLyS) Therapy in systemic lupus erythematosus (SLE) patients. Lupus 2008; 17:031
Furie R, Petri M, Zamani O,et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-30.
Dall Era M, Chakravarty E, Wallace D, Et Al. Reduced B Lymphocyte and immunoglobulin levels after atacicep treatment in patients with SLE: results of a multicenter, phase IB, doublé blind, placebo controlled, dose-escalating trial. Arthritis Rheum 2007; 56:4142-50
Papp KA, Henniger E. Evaluation of efazumab using safe psoriasis control. BCM Dematol 2006; 6:8
Usmani N, Goodfield M. Efalizumab in the treatment of discoid lupus erythematosus. Arch Dermatol 2007; 143:873-77
Janeway CA, Bottomly K. Signals and signs for lymphocyte responses. Cell 1994; 76:275-85
Boumpas DT, Furie r, Manzi S et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferaative lupus glomerulonephritis. Arthritis Rheum 2003; 48:719-727
Kalunian KC, Davis JC, Merrill JT et al. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a radomized, doublé blind, placebo control study. Arthritis Rheum 2002; 46:3251-3258
Davidson A, Diamond B, Wofsy D et al. Block and tackle: CTLA4lg takes on lupus. Lupus 2005; 14:197-203
Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4lg. Science 1994; 265:1225-27
Daikh DI, Wofsy D. Cutting edge: reversal or murine lupus nephiritis with CTLA4lg and cyclophosphamide. J Immunol 2001; 166:2913-16
Cunnane G, Chan OT, Cassafer G et al. Prevention of renal damage in murine lupus nephiritis by CTLA4 and cyclophosphamide. Arthritis Rheum 2004; 50:1539-48
Lipsky E. Interleukin 6 and rheumatic diseases. Arthritis Research and therapy 2006; 8 Suppl2.
Shirota Y, Yarbora C, Sims G et al. The impact of in vitro antireceptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Arthritis Rheum 2005; 52:S697
Tahir H, Isenberg D. Novel therapies in lupus nephritis lupus 2005; 14:77-82
Aringer M, Graninger WB, Sreiner G et al. Safety and efficacy of tumor necrosis factor alpha blockade in systematic lupus erythematosus: an open-label study. Arthritis Rheum 2004; 50:3161-69
Bao L, Osawe I, Puri T et al. C5a promotes development of experimental lupus nephritis wich can be blocked with a specific receptor antagonist. Eur J Immunol 2005; 35:2496-2506.
Molina H. Update on complement in the pathogenesis of SLE. Curr Op Rheum 2002; 14:492-7
Jones DS, Batstad PA, Field MJ et al. Immunospecific reduction of antioligonucleotide antibody-firming cells with tetrakisoligonucleotide conjugate (LPJ394), a therapeutic candidatrfor the treatment of lupus nephritis. J Med Chem 1995; 38:2138-44
Cardiel MH. Abetimus sodium: a new therapy for delaying the time to, and reducing the indence of, renal flare and/or major systemic lupus erythematosus flares in patients with systemic lupus erythematosus who have a history of renal disease. Expert Opin Investig Drugs 2005; 14:77-88
Weisman MH, Bluestein HG, Berner CM et al. Reduction in circulating dsDNA antibody titer after administration of LJP 394. J Rheumatol 1997; 24:314-18
58. Furie RA, Cash JM, Cronin ME et al. Treatment of systemic lupus erythematosus with LJP 294. J Rheumatol 2001; 28:257-265
Strand V, Aranow C, Cardiel MH et al. Imrpovement in health-related quality of life in systematic lupus evythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo. Lupus 2003; 12:677-686
Alarcon Segocia D, Tumalin JA, Furie RA et al. LJP 394 for the prevention of renal flare in pantients with systemic lupus evythematosus: results from a randomized, doublé blind, placebo controlled study. Arthritis Rheum 2003; 48:442-454
Luger D, Dayan M, Zinger H et al. A peptide base don the complementarity determining región 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation. J Clin Immunol 2004; 24:579-90
Roonblom L, Pascual V. The innate immune system in SLE: type I interferons and dendritic cells. Lupus 2008; 17:394-99
Wallace DC, Petri M, Olsen N et al. MEDI-545, an anti-interferin alpha monoclonal antibody, shows evidence of clinical activity in systematic lupus erythematosus. Arthritis Rheum 2007; 56:S526-S527.
Blomberg S, eloranta ML, Magnusson M et al. Expression of the marñers BDCA-2 and 4 production of interferón by plasmocitoid dendritic dell in systemic lupus erythematosus. Arthritis Rheum 2003; 48:2524-2532
Lafyatis R, Marshak-Rothistin A. Toll like receptors and innate immune responses in systemic lupus erythematosus. Arthritis Res Ther 2007; 9:222-228
Furst, D Stem cell transplantion for autoinmune disease: progress and problems. Curr.Op.Rheum 2002;14:220-24
Petri M, Jones RJ, Brodsky RA. High dose cyclophosphamide without stem cell trasplantion in systemic lupus erythematosus. Arthritis & Rheum 2003; 48:166-75.
Downloads
Published
Issue
Section
License
Copyright (c) 2011 Universidad Nacional de Córdoba
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The generation of derivative works is allowed as long as it is not done for commercial purposes. The original work may not be used for commercial purposes.
How to Cite
